cdk2 inhibitor azd8421
Generic: CDK2 Inhibitor AZD8421
cdk2 inhibitor azd8421: 1 clinical trial tracked.
cdk2 inhibitor azd8421 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about cdk2 inhibitor azd8421, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Primary endpoint: Incidence of dose limiting toxicities (DLTs) as defined in the protocol.
Interventionalopen564 targetStarted 2023-12Completion 2027-0814 sites · Australia, South Korea, Spain, United Kingdom…AstraZeneca